Table 2

SNPs significantly correlating with CFT response 3 or 12 months after treatment onset (primary and secondary outcome measure) in a dominant model, and p values of correlation with response. Not significant (p>0.05). The ORs for association are also tabulated, and represent the risk for non-response if the SNP is present at least once

SNP	Gene	Genome position	Minor allele	Minor allele frequency (%)	P value	OR (95% range)
SNPs significantly correlating with CFT response after 3months
rs55667289	FLT4	chr5:180 621 641	G	0.4	0.0005	0.746 (0.63 to 0.88)
rs7691507*	KDR	chr4:55 076 834	C	20.7	0.0051	1.056 (1.02 to 1.10)
rs5758223	MIR1281	chr22:41 093 916	G	26.0	0.0115	0.954 (0.92 to 0.99)
rs9513070	FLT1	chr13:28 305 702	G	38.2	0.0204	1.045 (1.01 to 1.09)
rs4820431	EP300	chr22:41 153 917	A	35.8	0.0232	0.958 (0.92 to 0.99)
rs3025035	VEGFA	chr6:43 783 622	T	6.3	0.0428	0.945 (0.90 to 1.00)
rs2305945	KDR	chr4:55 105 679	T	32.9	0.0472	0.963 (0.93 to 1.00)
SNPs significantly correlating with CFT response after 12months
rs3775194	VEGFC	chr4:176 702 723	G	39.2	0.0006	1.089 (1.04 to 1.14)
rs12054587	VEGFC	chr4:176 757 527	A	9.7	0.0048	1.106 (1.03 to 1.19)
rs2046462	VEGFC	chr4:176 681 324	C	29.6	0.0064	1.067 (1.02 to 1.12)
rs17086609	FLT1	chr13:28 355 574	G	33.3	0.0076	1.067 (1.02 to 1.12)
rs9551462	FLT1	chr13:28 378 967	T	35.0	0.0207	1.057 (1.01 to 1.11)
rs20551	EP300	chr22:41 152 004	G	28.0	0.0222	1.056 (1.01 to 1.11)
rs7691507*	KDR	chr4:55 076 834	C	20.7	0.0256	1.058 (1.01 to 1.11)
rs2820037	/	chr1:239 273 242	T	11.8	0.0267	0.934 (0.88 to 0.99)
rs10020464	KDR	chr4:55 112 903	T	32.0	0.0379	0.952 (0.91 to 1.00)
rs12510099	VEGFC	chr4:176 681 802	A	10.5	0.0451	1.064 (1.00 to 1.13)

CFT, central foveal thickness; SNP, single nucleotide polymorphism.